BIOTECHNOLOG Y C O R P O R AT E D E C K September 2020 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements, including: the expected timing of date from the 24 week endpoints from Unity's Phase 2 clinical study and Phase 1b high-dose, repeat-dose clinical study of UBX0101, statements regarding UNITY's understanding of cellular senescence and the role it plays in osteoarthritis and retinal diseases, the potential for U ...